Prevalence of MGUS by sex, age at exposure, and exposure dose by ABS93D
| Sex . | Male . | Female . | Total . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age at exposure . | 0-9 y . | 10-19 y . | 20-29 y . | ≥ 30 y . | All ages . | 0-9 y . | 10-19 y . | 20-29 y . | ≥ 30 y . | All ages . | 0-9 y . | 10-19 y . | 20-29 y . | ≥ 30 y . | All ages . |
| ABS93D dose | |||||||||||||||
| 0 to < 0.01 Gy | |||||||||||||||
| No. participants | 238 | 207 | 57 | 35 | 537 | 336 | 382 | 306 | 111 | 1135 | 574 | 589 | 363 | 146 | 1672 |
| No. cases | 3 | 7 | 3 | 0 | 13 | 3 | 3 | 5 | 3 | 14 | 6 | 10 | 8 | 3 | 27 |
| Prevalence, % | 1.3 | 3.4 | 5.3 | 0 | 3.7 | 0.9 | 0.8 | 1.6 | 2.7 | 1.2 | 1.1 | 1.7 | 2.2 | 2.1 | 1.6 |
| 0.01 to < 0.1 Gy | |||||||||||||||
| No. participants | 288 | 245 | 34 | 40 | 607 | 336 | 357 | 292 | 127 | 1094 | 624 | 602 | 326 | 167 | 1719 |
| No. cases | 5 | 4 | 3 | 4 | 16 | 4 | 6 | 6 | 2 | 18 | 9 | 10 | 9 | 6 | 34 |
| Prevalence, % | 1.7 | 1.6 | 8.8 | 10 | 2.7 | 1.2 | 1.7 | 2.1 | 1.6 | 1.6 | 1.4 | 1.7 | 2.8 | 3.6 | 2.0 |
| ≥ 0.1 Gy | |||||||||||||||
| No. participants | 164 | 225 | 51 | 29 | 469 | 195 | 315 | 219 | 82 | 811 | 359 | 540 | 270 | 111 | 1280 |
| No. cases | 3 | 14 | 0 | 2 | 19 | 1 | 7 | 3 | 2 | 13 | 4 | 21 | 3 | 4 | 32 |
| Prevalence, % | 1.8 | 6.2 | 0 | 6.9 | 4.1 | 0.5 | 2.2 | 1.4 | 2.4 | 1.6 | 1.1 | 3.9 | 1.1 | 3.6 | 2.5 |
| Total | |||||||||||||||
| No. participants | 690 | 677 | 142 | 104 | 1613 | 867 | 1054 | 817 | 320 | 3058 | 1557 | 1731 | 959 | 424 | 4671 |
| No. cases | 11 | 25 | 6 | 6 | 48 | 8 | 16 | 14 | 7 | 45 | 19 | 41 | 20 | 13 | 93 |
| Prevalence, % | 1.6 | 3.7 | 4.2 | 5.8 | 3.0 | 0.9 | 1.5 | 1.7 | 2.2 | 1.6 | 1.2 | 2.4 | 2.1 | 3.1 | 2.0 |
| Sex . | Male . | Female . | Total . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age at exposure . | 0-9 y . | 10-19 y . | 20-29 y . | ≥ 30 y . | All ages . | 0-9 y . | 10-19 y . | 20-29 y . | ≥ 30 y . | All ages . | 0-9 y . | 10-19 y . | 20-29 y . | ≥ 30 y . | All ages . |
| ABS93D dose | |||||||||||||||
| 0 to < 0.01 Gy | |||||||||||||||
| No. participants | 238 | 207 | 57 | 35 | 537 | 336 | 382 | 306 | 111 | 1135 | 574 | 589 | 363 | 146 | 1672 |
| No. cases | 3 | 7 | 3 | 0 | 13 | 3 | 3 | 5 | 3 | 14 | 6 | 10 | 8 | 3 | 27 |
| Prevalence, % | 1.3 | 3.4 | 5.3 | 0 | 3.7 | 0.9 | 0.8 | 1.6 | 2.7 | 1.2 | 1.1 | 1.7 | 2.2 | 2.1 | 1.6 |
| 0.01 to < 0.1 Gy | |||||||||||||||
| No. participants | 288 | 245 | 34 | 40 | 607 | 336 | 357 | 292 | 127 | 1094 | 624 | 602 | 326 | 167 | 1719 |
| No. cases | 5 | 4 | 3 | 4 | 16 | 4 | 6 | 6 | 2 | 18 | 9 | 10 | 9 | 6 | 34 |
| Prevalence, % | 1.7 | 1.6 | 8.8 | 10 | 2.7 | 1.2 | 1.7 | 2.1 | 1.6 | 1.6 | 1.4 | 1.7 | 2.8 | 3.6 | 2.0 |
| ≥ 0.1 Gy | |||||||||||||||
| No. participants | 164 | 225 | 51 | 29 | 469 | 195 | 315 | 219 | 82 | 811 | 359 | 540 | 270 | 111 | 1280 |
| No. cases | 3 | 14 | 0 | 2 | 19 | 1 | 7 | 3 | 2 | 13 | 4 | 21 | 3 | 4 | 32 |
| Prevalence, % | 1.8 | 6.2 | 0 | 6.9 | 4.1 | 0.5 | 2.2 | 1.4 | 2.4 | 1.6 | 1.1 | 3.9 | 1.1 | 3.6 | 2.5 |
| Total | |||||||||||||||
| No. participants | 690 | 677 | 142 | 104 | 1613 | 867 | 1054 | 817 | 320 | 3058 | 1557 | 1731 | 959 | 424 | 4671 |
| No. cases | 11 | 25 | 6 | 6 | 48 | 8 | 16 | 14 | 7 | 45 | 19 | 41 | 20 | 13 | 93 |
| Prevalence, % | 1.6 | 3.7 | 4.2 | 5.8 | 3.0 | 0.9 | 1.5 | 1.7 | 2.2 | 1.6 | 1.2 | 2.4 | 2.1 | 3.1 | 2.0 |